Entrepreneurship

Insulin delivery technology developed at UVA and commercialized by TypeZero Technologies, Inc. received initial support from UVA's Licensing and Ventures Group (LVG).

The UVA Licensing & Ventures Group (LVG) has invested in three Charlottesville-based ventures that grew out of University research. TypeZero Technologies Inc., TearSolutions Inc., and Mission Secure Inc.

Mission Secure Inc. recently announced the closing of an $8 million Series A financing round led by Energy Innovation Capital and Chevron Technology Ventures.

Professor Gregory B. Fairchild is the first director of Northern Virginia operations for the University of Virginia.

A WMRA podcast alludes to UVA's role in the biotechnology industry in Central Virginia.

Insulin delivery technology developed at UVA and commercialized by TypeZero Technologies, Inc. received initial support from UVA's Licensing and Ventures Group (LVG).

The UVA Licensing & Ventures Group (LVG) has invested in three Charlottesville-based ventures that grew out of University research. TypeZero Technologies Inc., TearSolutions Inc., and Mission Secure Inc.

Professor Gregory B. Fairchild is the first director of Northern Virginia operations for the University of Virginia.

Plans are underway to create ease of connection between UVA's Research Park, CHO, and the Hollymead Town Center to benefit Virginia visitors and businesses.

Plans are underway to create ease of connection between UVA's Research Park, CHO, and the Hollymead Town Center to benefit Virginia visitors and businesses.

UVA will receive funding to train teams of students and faculty research scientists to inspire effective innovation and entrepreneurial thinking.

The CvilleBioHub has been awarded over $80,000 from the GO Virginia initiative to expand and sustain the biotechnology ecosystem in the region.